An Own Label Supplier (OLS) is a company that sells a pharmaceutical product under its own brand name and logo, even though it does not manufacture the product itself.

Real-World Pharma Translation:When Tesco sells "Tesco Paracetamol":

Navigating MHRA variations is the core of OLS management. Here’s a breakdown of the most common scenarios.

Not every OLS needs a Wholesale Dealer Authorisation (WDA). The rules are specific and misinterpreting them is a common and costly error.

OLS lets distributors build brands and MA holders expand reach—but regulatory precision is non-negotiable. Master these rules, and you turn compliance into a competitive advantage.

🚀 Your Next MoveFor Regulatory Managers: Download our OLS Variation Checklist - link belowFor All: Got an OLS horror story? Share it in the comments!

Effortlessly ensure MHRA compliance and avoid costly rejections with this 3-step OLS variation checklist.

Product: Boots Paracetamol 500mg tablets (16s)Manufacturer: Aspar Pharmaceuticals LimitedDistributor: The Boots Company PLC​

The Error: Following a customer complaint, MHRA identified that foil blisters inside cartons incorrectly stated "Aspirin 300mg Dispersible Tablets" while containing paracetamol. Although tablets were confirmed as paracetamol, the mislabeling presented significant medication error risk.​

Consequence:

Root Cause: Packaging artwork control failure between manufacturer and OLS partner.

From January 1, 2025, all UK medicines must display a clearly legible "UK Only" label, with stickering permitted only until June 30, 2025. Companies failing to notify MHRA of artwork changes faced:​

Lesson: Proactive notification to MHRA (via self-certification or alongside other variations) prevented supply disruptions.​

Pre-Submission Triage:☑️ Is artwork last reviewed >5 years ago? → Flag mandatory PIQ requirement☑️ Does application bundle product name change? → Dual codes (B.II.b.1.z + A.2.b)☑️ Is this consequential to another approved variation? → Document justification​

Documentation Safeguards:☑️ PIL reuse declaration (avoids separate PIQ fee when using MA holder's leaflet)☑️ Consequential change justification clearly stated in cover letter☑️ Wholesale Dealer's Authorization copy (current and valid)​

Post-Submission Tracker:☑️ MHRA response deadline monitoring (60 days for Type IB)☑️ Variation approval → Artwork version control protocol activation☑️ QP sign-off before market release​

Question 1: Your central warehouse supplies 50 company-owned supermarkets. WDA needed?

Question 2: You franchise pharmacies under your brand name. Do franchisees need WDAs?

Question 3: You supply medicines to independent pharmacies for commercial profit. WDA needed?

MA Holder to OLS:"You handle artwork production costs and WDA compliance; we fast-track PIL reuse approval and provide regulatory support."

OLS to MA Holder:"Commit to 3-year minimum volume guarantees; we pay 100% of variation fees and provide market insights."

Own Label Supply enables distributors to build profitable pharmaceutical brands while allowing MA holders to expand market reach without direct retail operations. However, regulatory precision is non-negotiable. The distinction between "consequential" artwork changes and those requiring separate PIQ assessment can mean the difference between 60-day approval and 6-month delays.

Final Reminder: When in doubt about OLS artwork changes, always check the last approval date, consult MHRA guidance, and file appropriate variations. The cost of compliance is always less than the cost of non-compliance.​

This guide incorporates MHRA Marketing Authorisation Variations Supplementary Guidance (October 2025) and current fee schedules effective through March 2027. Always verify specific requirements with MHRA before submission.